EPS for Sarepta Therapeutics, Inc. (SRPT) Expected At $-0.57 as of July, 18

June 27, 2018 - By Sarah Harris

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Corporate Logo
Big Money Sentiment decreased to 0.97 in 2018 Q1. It has change of 0.25, from 2017Q4’s 1.22. The ratio turned negative due to Sarepta Therapeutics, Inc. positioning: 31 sold and 81 reduced. 45 funds amassed holdings and 64 increased holdings. Investors holded 52.88 million in 2017Q4 but now own 54.74 million shares or 3.52% more.
Sector Gamma As stated it has 51,006 shs. Natixis owns 7,612 shs for 0% of their capital. Rhumbline Advisers holds 60,859 shs or 0.01% of its capital. 96,213 were accumulated by Citigroup. J Goldman Com Ltd Partnership stated it has 0.14% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Howe & Rusling invested 0% of its capital in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Sit Inv Associates Inc owns 27,375 shs for 0.05% of their capital. Putnam Invs Ltd Liability invested 0% of its capital in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Century Companies Inc invested in 0% or 63,009 shs. State Of Wisconsin Inv Board has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Lpl Financial invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Ascend Capital Ltd Liability Company owns 63,919 shs for 0.19% of their capital. Atlantic Tru Grp Inc Ltd Liability Company has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 9,280 shs. Oak Ridge Investments Limited Liability Corporation has 131,334 shs. Comerica National Bank & Trust has 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 16,202 shs.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s earnings report is awaited on July, 18., as reported by RTT. Analysts predict $-0.57 earnings per share, which is $0.58 up or 50.43 % from 2017’s $-1.15 earnings per share. Wall Street sees 29.55 % negative EPS growth as of July, 18. SRPT hit $130.53 during the last trading session after $5 change.Sarepta Therapeutics, Inc. has volume of 768,120 shares. Since June 27, 2017 SRPT has risen 197.08% and is uptrending. The stock outperformed the S&P500 by 184.51%.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

In total 20 analysts cover Sarepta Therapeutics (NASDAQ:SRPT). “Buy” rating has 18, “Sell” are 0, while 2 are “Hold”. 90% are bullish. 36 are the (NASDAQ:SRPT)’s analyst reports since January 3, 2018 according to StockzIntelligence Inc. On Friday, January 19 Leerink Swann maintained the shares of SRPT in report with “Buy” rating. On Thursday, March 15 the firm earned “Buy” rating by SunTrust. In Friday, May 4 report Credit Suisse maintained the stock with “Outperform” rating. On Thursday, June 21 Robert W. Baird maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating. Robert W. Baird has “Buy” rating and $20200 target. On Thursday, May 3 the rating was downgraded by Oppenheimer to “Hold”. On Friday, March 2 the firm has “Buy” rating by Piper Jaffray given. On Wednesday, June 20 the stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Equal-Weight” rating by Morgan Stanley. On Friday, May 11 the firm earned “Overweight” rating by Barclays Capital. On Thursday, June 21 the firm has “Buy” rating given by Nomura. On Wednesday, February 21 the stock has “Overweight” rating by JP Morgan.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases.The firm is valued at $8.55 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.Last it reported negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

For more Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news brought out recently go to: Fool.com, Seekingalpha.com, Fool.com, Seekingalpha.com or Fool.com. The titles are as follows: “Is Sarepta Therapeutics Stock Headed to Over $200 a Share?” brought out on June 21, 2018, “Gene Therapy For Duchenne” on June 20, 2018, “Why Sangamo Therapeutics Stock Is Spiking Today” with a publish date: June 20, 2018, “Sarepta Therapeutics: Chasing The Good News” and the last “3 Biotech Stocks That Soared This Week: Are They Buys?” with publication date: June 23, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.